Celadon Pharmaceuticals (CEL) Stock Chart & Stock Price History GBX 13.40 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsHeadlinesBuy This Stock Celadon Pharmaceuticals Stock Price Performance The Celadon Pharmaceuticals (CEL) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 82.13%, with a year-to-date return of -4.29%. In the past month, the stock has increased 11.67%, reflecting recent market activity. As of the latest close, Celadon Pharmaceuticals traded at GBX 13.40 with a market cap of £8.22 million and volume of 126,053 shares. Receive CEL Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+48.89%1 Month Performance+11.67%3 Month Performance+226.03%Year-To-Date Performance-4.29%1 Year Performance-82.13% CEL Stock Chart for Saturday, July, 5, 2025 CEL Chart by TradingView Celadon Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/03/2025GBX 13.40GBX 13.40GBX 13.40GBX 13.40126,053 shs£8.22 million07/02/2025GBX 9GBX 13.40+48.89%GBX 13.45GBX 5126,053 shs£8.22 million07/01/2025GBX 9GBX 9GBX 13.45GBX 5168,842 shs£5.52 million06/30/2025GBX 13.78GBX 9-34.66%GBX 13.45GBX 5168,842 shs£5.52 million06/27/2025GBX 13.79GBX 13.78-0.11%GBX 13.78GBX 928,293 shs£8.45 million06/26/2025GBX 10.08GBX 13.79+36.75%GBX 13.80GBX 9146,971 shs£8.46 million06/25/2025GBX 10GBX 10.08+0.84%GBX 14GBX 10.0842,007 shs£6.19 million06/24/2025GBX 10GBX 10GBX 14GBX 1011,871 shs£6.13 million06/23/2025GBX 10.20GBX 10-1.96%GBX 14GBX 1030,223 shs£6.13 million06/20/2025GBX 10.20GBX 10.20GBX 14GBX 10.208,158 shs£6.26 million Get the Latest News and Ratings for CEL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 06/19/2025GBX 10GBX 10.20+2.00%GBX 15GBX 1012,066 shs£6.26 million06/18/2025GBX 15GBX 10-33.33%GBX 15GBX 1017,375 shs£6.13 million06/17/2025GBX 11.30GBX 15+32.74%GBX 15GBX 1098,550 shs£9.20 million06/16/2025GBX 14.70GBX 11.30-23.13%GBX 15GBX 10.50185,940 shs£6.93 million06/13/2025GBX 10GBX 14.70+47.00%GBX 15GBX 12.5090,689 shs£9.02 million06/12/2025GBX 12.02GBX 10-16.82%GBX 15.90GBX 10192,998 shs£6.13 million06/11/2025GBX 14.65GBX 12.02-17.94%GBX 17GBX 12367,728 shs£7.37 million06/10/2025GBX 12.73GBX 14.65+15.08%GBX 15GBX 11209,703 shs£8.99 million06/09/2025GBX 8.48GBX 12.73+50.12%GBX 15GBX 10.20143,316 shs£7.81 million06/06/2025GBX 12GBX 8.48-29.33%GBX 15GBX 8.48102,845 shs£5.20 million06/05/2025GBX 15GBX 12-20.00%GBX 15GBX 1296,856 shs£7.36 million06/04/2025GBX 14.76GBX 15+1.63%GBX 15GBX 12485,542 shs£9.20 million Related Companies Cambridge Nutritional Sciences Stock Chart Beacon Energy Stock Chart Fox Marble Stock Chart Vodafone Group Public Stock Chart BT Group Stock Chart BBGI Global Infrastructure Stock Chart Pacific Horizon Investment Trust Stock Chart Shield Therapeutics Stock Chart Provexis Stock Chart N4 Pharma Stock Chart Receive CEL Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (LON:CEL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
